Inspira Technologies deploys ART100 in New York

Inspira Technologies announced the deployment and initiation of a structured commercial evaluation of its U.S. Food and Drug Administration (FDA)-cleared INSPIRA ART100 system at a new and additional leading U.S. academic medical center. This institution is a prominent health system in United States===New York (state), ranked among the top 10 hospitals by Newsweek. This deployment expands Inspira Technologies' presence within the Tier-1 U.S. hospital market and integrates the ART100 system into the center's clinical workflow for evaluation. Mike Hershkovitz, Global VP Sales at Inspira Technologies, highlighted this as a continued execution of their U.S. commercial strategy, aiming to convert these high-profile evaluations into a sustainable commercial pipeline and expand their footprint across key U.S. markets. The INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S.